Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients

Oda Jensen, Andreas Kiesbye Øvlisen, Lasse Hjort Jakobsen, Anne Stidsholt Roug, René Ernst Nielsen, Claus Werenberg Marcher, Lene Hyldahl Ebbesen, Kim Theilgaard-Mönch, Peter Møller, Claudia Schöllkopf, Christian Torp-Pedersen, Tarec Christoffer El-Galaly, Marianne Tang Severinsen*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

23 Downloads (Pure)

Abstract

Introduction: The diagnosis of a life-threatening disease can lead to depression and anxiety resulting in pharmacological treatment. However, use of psychotropic drugs (antidepressants, anxiolytics, and antipsychotics) in acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) is undetermined. Methods: Prescription of psychotropic drugs in Danish AML and MDS patients was compared to a cohort matched on age, sex, and country of origin from the Danish background population using national population-based registries. Results: In total, 2404 AML patients (median age 69 years) and 1307 MDS patients (median age 75 years) were included and each matched to five comparators from the background population. Two-year cumulative incidences showed that AML (20.6%) and MDS (21.2%) patients had a high risk of redemption of a psychotropic drug prescription compared to the background population (7.0% and 7.9%). High age, low educational level, and Charlson Comorbidity Index score ≥1 was associated with a higher risk in AML and MDS patients. Furthermore, non-curative treatment intent and performance status in AML patients, and high risk MDS were associated with elevated risk of psychotropic drug prescription. Conclusion: In conclusion, diagnoses of AML and MDS were associated with a higher rate of psychotropic drugs prescription compared to the background population.

Original languageEnglish
JournalClinical Epidemiology
Volume14
Pages (from-to)225-237
ISSN1179-1349
DOIs
Publication statusPublished - 2022

Bibliographical note

Publisher Copyright:
© 2022 Jensen et al.

Keywords

  • Acute myeloid leukaemia
  • Anxiety
  • Depression
  • Myelodysplastic syndrome
  • Psychotropic drugs

Fingerprint

Dive into the research topics of 'Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients'. Together they form a unique fingerprint.

Cite this